According to a scoping review published in the Journal of Clinical Medicine (July 2026), electroconvulsive therapy and repetitive TMS are the two most evidence-supported brain stimulation therapies for treatment-resistant depression, with TMS increasingly preferred for its comparable efficacy and significantly cleaner side effect profile. That comparison looks very different in 2026 than it did even […]
According to a comprehensive narrative review published in Brain Sciences (MDPI, November 2025), deep brain stimulation (DBS) demonstrates clinically meaningful symptom reductions across psychiatric conditions, with response and remission rates for depression approaching 48% and 35%, respectively, in patients who had already exhausted every other available treatment. That context is everything. TMS vs DBS is […]
According to a 2025 consensus review endorsed by the National Network of Depression Centers, drawing on nearly 2,400 studies, TMS is safe and effective even for individuals whose depression has not responded to medications, with up to 83% of patients showing measurable improvement in real-world clinical settings. That figure sits at the non-invasive end of […]
According to a 2025 individual participant data analysis published in eClinicalMedicine (The Lancet), intranasal esketamine does not appear to be more effective than TMS for treatment-resistant depression; TMS was found to be similarly effective, or potentially even superior, to Spravato across key outcomes. That is a striking finding, especially for patients who assume a medication-based […]
According to a systematic review and meta-analysis published in the Journal of Affective Disorders (Rakesh et al., August 2024), According to a naturalistic study published in PLOS ONE (PubMed, 2022), both TMS and intramuscular ketamine produced equally significant reductions in depression and anxiety symptoms in treatment-resistant patients, with no statistically meaningful difference in response or […]
According to a systematic review and meta-analysis published in the Journal of Affective Disorders (Rakesh et al., August 2024), active TMS combined with antidepressant medication produced significantly greater improvement in major depressive disorder than sham TMS combined with the same medications, with a large effect size that held across multiple trials. That finding points to […]
According to the U.S. Food and Drug Administration, TMS has received FDA clearance for major depressive disorder, obsessive-compulsive disorder, smoking cessation, and anxious depression, while MeRT, as of 2025, has not yet received FDA clearance for any specific condition, with its pivotal PTSD trial still under review (FDA Device Database, 2025). That single fact frames […]
Most families don’t see it coming. An older parent starts canceling plans. A grandparent who used to sleep soundly is now up at 3 a.m. A husband who never complained about his health is suddenly convinced something is seriously wrong – every other week. These aren’t just personality quirks or signs of getting older. They’re […]
The treatment for claustrophobia is more accessible than most people realize – and more effective than simply “toughing it out.” For millions of people, a ride in an elevator, a crowded subway car, or even a small windowless office can trigger a wave of fear so intense it becomes physically overwhelming. Claustrophobia isn’t just discomfort. […]
Suicidal thoughts are not a personal failure – they are a sign that something is wrong and that the mind needs real, targeted help. For many people, these thoughts arrive quietly, building pressure over time until they feel impossible to ignore. The good news is that suicidal thoughts are treatable. With the right support network […]
